Document is current
Any future updates will be listed below
-
Authors
Titeca, Kevin https://orcid.org/0000-0002-7677-8252
Chiapparino, Antonella
Hennrich, Marco L. https://orcid.org/0000-0003-2853-9748
Türei, Dénes https://orcid.org/0000-0002-7249-9379
Moqadam, Mahmoud https://orcid.org/0000-0002-3456-5064
Talandashti, Reza https://orcid.org/0000-0003-4087-475X
Cuveillier, Camille https://orcid.org/0000-0003-2081-1938
van Ek, Larissa https://orcid.org/0000-0002-8047-1560
Zukowska, Joanna https://orcid.org/0000-0001-8287-7428
Triana, Sergio https://orcid.org/0000-0003-0370-7821
Echelard, Florian
Nielsen, Inger Ødum
Foged, Mads Møller https://orcid.org/0000-0003-2225-6114
Gehin, Charlotte
Olechnovic, Kliment
Grudinin, Sergei https://orcid.org/0000-0002-1903-7220
Saez-Rodriguez, Julio https://orcid.org/0000-0002-8552-8976
Alexandrov, Theodore https://orcid.org/0000-0001-9464-6125
Maeda, Kenji https://orcid.org/0000-0002-9080-5691
Reuter, Nathalie https://orcid.org/0000-0002-3649-7675
Gavin, Anne-Claude https://orcid.org/0000-0003-4917-2340
- License Information
-
More Information
Article History
Received: 12 January 2024
Accepted: 11 December 2025
First Online: 7 January 2026
Competing interests
: A.-C.G. reports funding from Lipotype GmbH, Dresden Germany. J.S.-R. reports funding in the last three years from GSK and Pfizer and fees or honoraria from Travere Therapeutics, Stadapharm, Astex, Owkin, Pfizer, Vera, Grunenthal, Tempus and Moderna. M.L.H. is currently employed by Absea Biotechnology GmbH, Berlin, Germany. I.Ø.N. is currently employed by Novo Nordisk, Bagsværd, Denmark and A.C. is currently employed by AB Sciex Germany GmbH. T.A. is a co-founder and shareholder of DeepCyte Inc. and Metacloud Inc. M.M.F. is currently the owner of MM Foged Consulting. The other authors declare no competing interests.
